Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 10/20 | 0.36 |
| ▸ | KDR | P35968 | 10/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568591 | 0.86 | FLT1 (0.38) | FLT1KDRMAPK1KMT2AL3MBTL1 | |
| SCHEMBL22125947 | 0.85 | FLT1 (0.38) | FLT1KDRCNR2MAPK1 | |
| SCHEMBL31582206 | 0.85 | FLT1 (0.38) | FLT1KDRCNR2MAPK1 | |
| SCHEMBL31582304 | 0.85 | FLT1 (0.38) | FLT1KDRCNR2MAPK1 | |
| SCHEMBL25562724 | 0.84 | CNR2 (0.34) | FLT1KDRCNR2 | |
| SCHEMBL25568592 | 0.84 | MAPK1 (0.36) | FLT1KDRCNR2MAPK1KMT2A | |
| SCHEMBL22125614 | 0.83 | FLT1 (0.37) | FLT1KDRCNR2MAPK1 | |
| SCHEMBL25862645 | 0.83 | FLT1 (0.35) | FLT1KDRCNR2MAPK1KMT2A | |
| SCHEMBL25564515 | 0.82 | MAPK1 (0.35) | FLT1KDRCNR2MAPK1KMT2A | |
| SCHEMBL25564501 | 0.81 | FLT1 (0.39) | FLT1KDRCNR2MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | FLT1 3452/4885KDR 4480/4885CNR2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.